UBS Group
PHXM

UBS Group’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

UBS Group’s Portfolio PHXM Stock Details PHXM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7
Closed -$36 – 10270
2023
Q3 		$36 Buy
+7
New +$39 ﹤0.01% 9055
2023
Q2 		– Sell
-55
Closed -$539 – 10014
2023
Q1 		$539 Sell
55
-421
-88% -$3.25K ﹤0.01% 8982
2022
Q4 		$1.57K Buy
476
+44
+10% +$258 ﹤0.01% 9837
2022
Q3 		$2K Sell
432
-439
-50% -$4.35K ﹤0.01% 9828
2022
Q2 		$10K Buy
+871
New +$10.8K ﹤0.01% 8040
2022
Q1 		– Sell
-358
Closed -$8K – 11153
2021
Q4 		$8K Buy
+358
New +$12.1K ﹤0.01% 9078
2018
Q4 		– Sell
-125
Closed -$11K – 8386
2018
Q3 		$11K Buy
125
+7
+6% +$730 ﹤0.01% 7129
2018
Q2 		$13K Hold
118
– – ﹤0.01% 7004
2018
Q1 		$25K Sell
118
-46
-28% -$9.8K ﹤0.01% 6259
2017
Q4 		$36K Buy
+164
New +$38.7K ﹤0.01% 6107

Other funds holding PHXM

ADL
Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

UBS Group's PHXM Position: Q4 2023 in Review

UBS Group sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q4 2023, closing a stake of 7 shares — an estimated $36 sold.

UBS Group first reported a position in PHXM in Q4 2017 and held it in 10 quarters. The position peaked at $36K in Q4 2017. 1 fund tracked by Wall St. Rank holds PHXM as of Q4 2023.

  • UBS Group reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 7 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q4 2023, an estimated $36.
  • UBS Group first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q4 2017 and held it in 10 quarters.
  • UBS Group's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $36K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.